Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

NCT07223424 is registered in ClinicalTrials.gov with Diwakar Davar as lead sponsor.

NCT NCT07223424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07223424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)
Lead sponsor
Diwakar Davar
Phase
Phase 2
Overall status
Recruiting
Start date
November 4, 2025
Completion date
November 30, 2030
Enrollment
880 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, colo-rectal cancer (dmmr/msi-h crc), esophageal adenocarcinoma, esophageal cancer, gastric/gej, gastro-esophageal adenocarcinoma, hepatocellular carcinoma, melanoma, non small cell lung cancer, renal cell carcinoma, squamous cell carcinoma, ulcerative colitis